Aurora Cannabis Inc. (ACB) vs Inhibikase Therapeutics, Inc. (IKT)
A side-by-side comparison of Aurora Cannabis Inc. and Inhibikase Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACB
Aurora Cannabis Inc.
$4.50HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT
IKT
Inhibikase Therapeutics, Inc.
$1.99HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT
Total return — ACB vs IKT
growth of $100 · dividends reinvested · last 6yACB -95.0% (-39.3%/yr)IKT -96.6% (-43.2%/yr)ACB compounded faster over this window
ACB IKT
ACB vs IKT: by the numbers
- •ACB is the larger company ($279M vs $262M market cap).
- •Both run net losses; IKT's is the smaller (0.00% vs -38.13% net margin).
Metrics side by side
Valuation
| Metric | ACB | IKT |
|---|---|---|
| P/S ratio | 1.34 | N/A |
| P/B ratio | 0.75 | 1.71 |
Profitability
| Metric | ACB | IKT |
|---|---|---|
| Gross margin | 42.62% | 0.00% |
| Operating margin | -14.55% | 0.00% |
| Net margin | -38.13% | 0.00% |
| ROE | -21.41% | -39.55% |
| ROIC | -15.69% | -42.92% |
Growth (annualized)
| Metric | ACB | IKT |
|---|---|---|
| Revenue CAGR (5Y) | 1.68% | N/A |
| Total return CAGR (5Y) | -42.83% | -29.10% |
Frequently asked
- How have ACB and IKT total returns compared?
- Over the past 5 years, ACB delivered -42.83% and IKT delivered -29.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.